Monday - May 25, 2026
Johnson & Johnson statement on investigational programs in large B-cell lymphoma
April 30, 2026
NEW BRUNSWICK, New Jersey, April 30 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson statement on investigational programs in large B-cell lymphoma

*

RARITAN, N.J., APRIL 30, 2026 - The investigational CD20 mono CAR-T cell therapy and CD19-CD20 bi-CAR-T programs will be discontinued. This is a strategic business decision based on the Company's portfolio priorities and . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products